NeoThetis: Pan-Cancer Plus
NeoThetis Pan-Cancer Plus panel analyses 222 genes associated with different types of cancers. It can help identify genetic alterations that can be responsible for cancer development and therapy resistance in solid tumours. The clinical significance of the genes tested has been previously emphasised by professional bodies including and . Depending on the type of cancer and the genetic alterations identified, different /-approved drugs as well as eligible clinical trials are available.
Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. / approved immunotherapies, such as pembrolizumab, are also available for patients with MSI-high status depending on their type of cancer.
Blood-based Tumour Mutational Burden (bTMB) immunotherapy biomarker is also tested in this panel. bTMB is tumour agnostic and is applicable for all solid tumours, including rare types. It can guide healthcare providers to identify patients who might benefit from immunotherapy.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

